PressJanuary 4, 2024 Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
PressJanuary 4, 2024 SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
PressJanuary 4, 2024 Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
PressJanuary 4, 2024 atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
PressJanuary 2, 2024 atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
PressJanuary 2, 2024 BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
PressJanuary 2, 2024 Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
PressDecember 22, 2023 Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
PressDecember 21, 2023 Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
PressDecember 20, 2023 Filament Health Announces Termination of Proposed Business Combination With Jupiter Acquisition Corporation
PressDecember 19, 2023 Filament Health Announces Termination of Shareholder Meeting and Engagement of Donohoe Advisory for Compliance Expertise
PressDecember 18, 2023 Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer
PressDecember 18, 2023 Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
PressDecember 15, 2023 Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study
